|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||0.12 - 0.13|
|52 Week Range||0.04 - 0.28|
|PE Ratio (TTM)||3.87|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||0.13|
BioCorRx Inc. (BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today announced the Company recently sold 5.5 million shares of common stock in a private placement at a price of $0.20 per share for proceeds of $1.1 million. This capital is enabling BioCorRx to continue to work towards FDA approval of BICX102, the Company’s naltrexone implant for the treatment of opioid and alcohol use disorders. Brady Granier, President, CEO and Director, stated, “We are pleased to announce that our investors continue to support the management team at BioCorRx and the future growth and success of the Company.
BioCorRx Inc. (BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today announced it has submitted a grant application to the National Institutes of Health (NIH) to fund the development and study plans for BICX102, the Company’s sustained release naltrexone implant for the treatment of opioid and alcohol use disorders. This specific grant opportunity, Development of Medications to Prevent and Treat Opioid Use Disorders and Overdose (UG3/UH3), was created as a result of the current opioid epidemic. Brady Granier, President, CEO and Director, stated, “The NIH provides support for the research and development of new treatments that can help address the current epidemic of opioid use disorder, which is estimated to affect over 2 million Americans. We are seeking funding from the NIH that could potentially cover the entire cost of the BICX102 development plan.
BioCorRx, Inc. (BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of substance use disorders, today provided a business update for the first quarter ended March 31, 2018. In January, BioCorRx®, in collaboration with One Day at a Time Program (ODAAT), announced a pilot for the BioCorRx® Recovery Program in Philadelphia, Pennsylvania.
BioCorRx Inc. (OTCQB: BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today reported that Dr. Mark Siegel, commented on the advantages of sustained release naltrexone implants in treating addiction on Varney & Co. on Fox Business. The interview follows a similar report on Fox Business with actor Jeremy Miller, best known for his role as Ben Seaver on the hit TV show Growing Pains, in which Mr. Miller discussed how BioCorRx’s sustained release naltrexone has changed his life.
Mr. Miller discussed his personal experience with alcoholism and how the implant has been “an absolute game changer” after trying other treatments, unsuccessfully. In discussing the implant, he noted, “Within hours I started noticing the effects, and what you notice is what’s not there – that constant obsessive need, it just kind of vanished.
NEW YORK, NY / ACCESSWIRE / March 20, 2018 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced it has issued ...
NEW YORK, NY / ACCESSWIRE / February 26, 2018 / Latest key findings by Growth Market Report for all traders, shareholders, and investors of Biocorrx, Inc. (OTCQB: BICX) and Repro-Med Systems, Inc. (OTCQX: ...